Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127796 | 1.00 | POLB (0.41) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10127792 | 0.94 | POLB (0.38) | POLBKDM4EATML3MBTL1TYMS | |
| SCHEMBL10127850 | 0.94 | POLB (0.38) | POLBKDM4EATML3MBTL1TYMS | |
| SCHEMBL10127711 | 0.91 | POLB (0.45) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10127842 | 0.90 | POLB (0.41) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10127778 | 0.90 | POLB (0.41) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10128532 | 0.87 | POLB (0.38) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10128710 | 0.87 | POLB (0.38) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10128426 | 0.84 | POLB (0.50) | POLBKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL10127834 | 0.84 | POLB (0.50) | POLBKDM4EALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| WO-2012017842-A1 | TRIAZOLE DERIVATIVE, HETEROCYCLIC COMPOUND, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | HTR3D, KCNQ4, KCNQ3 | POLB 3317/4885KDM4E 2008/4885ALDH1A1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.